Disruptive Psychopharmacology [electronic resource] / edited by Frederick S. Barrett, Katrin H. Preller.

Dosing psychedelics and MDMA -- Psychedelic Group Therapy -- Set and Setting: Aesthetic experiences and their contribution to psychedelic therapies -- Psychedelic-Assisted Therapy for Social Adaptability in Autistic Adults -- Foundations for Training Psychedelic Therapists -- Ayahuasca for the Treatment of Depression -- Psilocybin for the Treatment of Depression -- Ketamine for the Treatment of Depression -- The Potential of Psychedelics for End of Life and Palliative Care -- Psychedelic-Assisted Therapy for Addiction and Potential Mechanisms of Action -- Psilocybin for Tobacco Use Disorder -- Psychedelic Drugs as Anti-Inflammatory Agents -- Psilocybin for the Treatment of Obsessive-Compulsive Disorder -- Psilocybin for the Treatment of Headache and Pain Disorders -- Psilocybin for the Treatment of Neurodegenerative Disorders -- Psilocybin for Trauma-Related Disorders.

Psychedelic therapies are gaining traction as potential treatments for a wide range of indications, but the structure and delivery of psychedelic therapies are a sharp departure from more traditional models of psychotherapy and pharmacotherapy for psychiatric and other medical disorders. This may be critical to their success. The current volume provides a comprehensive review of the state of the science of psychedelic therapies, including discussion of models and approaches to psychedelic therapies as well as the current status of safety and efficacy data for mood, substance use, trauma, obsessive-compulsive, neurodevelopmental, neurodegenerative disorders, neurological, and inflammatory disorders.